- Home
- VUZI vs BDTX Comparison
VUZI vs BDTX Comparison
Compare VUZI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VUZI
- BDTX
- Stock Information
- Founded
- VUZI 1997
- BDTX 2014
- Country
- VUZI United States
- BDTX United States
- Employees
- VUZI N/A
- BDTX N/A
- Industry
- VUZI Industrial Machinery/Components
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VUZI Technology
- BDTX Health Care
- Exchange
- VUZI Nasdaq
- BDTX Nasdaq
- Market Cap
- VUZI 267.1M
- BDTX 220.3M
- IPO Year
- VUZI N/A
- BDTX 2020
- Fundamental
- Price
- VUZI $3.39
- BDTX $3.95
- Analyst Decision
- VUZI
- BDTX Strong Buy
- Analyst Count
- VUZI 0
- BDTX 5
- Target Price
- VUZI N/A
- BDTX $10.40
- AVG Volume (30 Days)
- VUZI 2.0M
- BDTX 812.4K
- Earning Date
- VUZI 11-13-2025
- BDTX 11-05-2025
- Dividend Yield
- VUZI N/A
- BDTX N/A
- EPS Growth
- VUZI N/A
- BDTX N/A
- EPS
- VUZI N/A
- BDTX 0.25
- Revenue
- VUZI $5,534,768.00
- BDTX $70,000,000.00
- Revenue This Year
- VUZI $22.67
- BDTX N/A
- Revenue Next Year
- VUZI $80.00
- BDTX N/A
- P/E Ratio
- VUZI N/A
- BDTX $15.76
- Revenue Growth
- VUZI N/A
- BDTX N/A
- 52 Week Low
- VUZI $0.85
- BDTX $1.20
- 52 Week High
- VUZI $5.79
- BDTX $4.45
- Technical
- Relative Strength Index (RSI)
- VUZI 47.72
- BDTX 55.41
- Support Level
- VUZI $3.27
- BDTX $3.71
- Resistance Level
- VUZI $3.64
- BDTX $4.08
- Average True Range (ATR)
- VUZI 0.25
- BDTX 0.24
- MACD
- VUZI -0.10
- BDTX -0.04
- Stochastic Oscillator
- VUZI 13.64
- BDTX 35.90
About VUZI Vuzix Corporation
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.